FIELD: molecular biology, medicine, endocrinology. SUBSTANCE: invention relates to glucagon receptors. Invention proposes the isolated DNA molecule encoding glucagon receptors or glucagon peptide receptors. DNA-construction provides expression of isolated DNA molecule and its insertion into cells of lines COS or BHK. Invention proposes also a method of preparing glucagon receptors involving culturing cell lines COS or BHK and isolation of the end product. Invention presents also a monoclonal antibody binding specifically with glucagon receptors and blocking glucagon binding with glucagon receptors. Invention relates to also a method of detection of glucagon antagonist involving agonist binding with isolated glucagon receptors. Invention can be associated with stimulation of glycolysis and glycogenolysis and study of glucagon role in diabetes mellitus etiology. EFFECT: improved method of preparing DNA, glucagon and peptide receptors. 13 cl, 5 dwg, 8 tbl
Title | Year | Author | Number |
---|---|---|---|
USE OF PHARMACEUTICAL COMPOSITION CONTAINING PEPTIDE SUPPRESSING APPETITE | 1997 |
|
RU2197261C2 |
NEW LIGAND OF CYTOKINE RECEPTOR ZCYTOR17 | 2003 |
|
RU2490276C2 |
METHOD OF HETEROLOGICAL PROTEIN PRODUCING | 1994 |
|
RU2143495C1 |
TOLEROGENIC DNA VACCINE | 2017 |
|
RU2752608C2 |
PROTEINS BINDING HUMAN ANTIGEN LIGAND CD30 | 2013 |
|
RU2650800C2 |
ANTIBODIES TO NKG2A AND THEIR APPLICATIONS | 2007 |
|
RU2499001C2 |
POLYPEPTIDE THROMBOPOIETIN (TPO), DNA ENCODING POLYPEPTIDE TPO (VERSIONS), METHOD OF PREPARING POLYPEPTIDE (VERSIONS), PHARMACEUTICAL COMPOSITION, METHOD OF TREATMENT (VERSIONS), ANTIBODY AGAINST POLYPEPTIDE TPO | 1995 |
|
RU2194074C2 |
GLUCAN ACTIVATOR RECEPTOR AND DNA MOLECULE ENCODING ITS | 1995 |
|
RU2146705C1 |
MODIFIED FACTOR VII | 1995 |
|
RU2214833C2 |
ISOLATED SOLUBLE IL-20 RECEPTOR (VARIANTS) | 2000 |
|
RU2279441C2 |
Authors
Dates
2002-07-10—Published
1993-08-30—Filed